Histone deacetylases (HDAC) have been implicated in prostate cancer progression, providing the rationale for pharmacological treatment of the disease with HDAC inhibitors (HDACi) (Abbas and Gupta, 2008). Here, HDAC9 is linked to prostate cancer.